Methohexital

Rapid Sedation

Drug Spotlight · IV Anesthetic · Barbiturate

TL;DR

Methohexital is a potent, ultra-short-acting intravenous medication used to put patients to sleep for very brief procedures. It works by keeping the brain’s inhibitory channels open longer, effectively shutting down consciousness in under a minute. It is uniquely famous in the modern era for allowing seizures to occur rather than stopping them, which is exactly why it is the gold standard for electroconvulsive therapy, but also why it carries significant medicolegal risk regarding airway management and physical injury from uncontrolled movements.

Identity

Chemical Profile

Chemical Structure

Chemical Name

5-allyl-1-methyl-5-(1-methyl-2-pentynyl)barbituric acid

Formulation

Methohexital comes as a freeze-dried powder that must be reconstituted with sterile water or normal saline (a 0.9 percent sodium chloride solution). When mixed, it forms a clear liquid with an intensely alkaline pH of 10 to 11. For context, a neutral pH is 7. I remember from my general chemistry prerequisites that solutions this basic are incredibly caustic, this is why it can cause severe tissue damage if the fluid leaks out of the vein into the surrounding skin.

Key Properties

Highly lipid-soluble: it dissolves effortlessly in fats, allowing it to cross the blood-brain barrier almost instantly after injection.
Rapid redistribution: the drug quickly vacates the brain to settle in muscle tissue, which is why a patient wakes up rapidly following a single dose.
Hepatic clearance: it is broken down by the liver roughly 3 to 4 times faster than older drugs in the barbiturate class.

Background

History

Nearly 70 years ago, anesthesiologists needed an intravenous agent that allowed patients to wake up faster than they did with older drugs like thiopental. Methohexital answered that call, enjoying widespread popularity for decades before eventually being sidelined by newer anesthetics for routine procedures.

1950s

Researchers at Eli Lilly successfully synthesize methohexital while systematically searching for a shorter-acting barbiturate compound that clears the body more efficiently.
1960

The drug receives approval from the FDA under the brand name Brevital. It quickly dominates the market for brief outpatient surgeries and dental procedures due to its impressively fast onset and offset.
1989

Propofol arrives on the United States market and fundamentally changes anesthesia. Propofol offers a smoother wake-up profile without the chaotic muscle twitching seen with methohexital, causing Brevital to fall out of routine favor.
2000s – Present

Methohexital finds a permanent, highly specific niche in psychiatric care as the preferred induction agent for electroconvulsive therapy. It secures this role precisely because it does not suppress seizure duration the way propofol does.

Pharmacology

How It Works

The brain communicates via constant electrical impulses. To quiet these signals down, the nervous system relies on a chemical neurotransmitter called gamma-aminobutyric acid (GABA). When GABA binds to a neuron, it opens a specialized channel that allows negatively charged chloride ions to flow inside. **This influx makes the inside of the cell more negative**, which acts as a powerful brake on electrical activity. Methohexital binds to these exact same receptors, but rather than just pressing the brake, **it keeps the chloride channels open for a significantly longer duration**. From this we can see that the neuron becomes flooded with negative charge, causing the patient to rapidly lose consciousness.

Because it dissolves so easily in fat, the drug is swept directly into the highly oxygenated brain tissue, rendering a patient unconscious in under one minute. The patient then wakes up just 5 to 7 minutes later, not because the body has destroyed the drug, but because of rapid redistribution. The active molecules literally wash out of the brain and sink into less vascular muscle and fat tissues. The standardized 5-minute offset time can be achieved via a single intravenous injection, meaning the provider has a strictly limited window to perform a procedure.

Dosing at a Glance

Induction (putting patient to sleep): ~1.0 to 1.5 mg/kg (milligrams of drug per kilogram of body weight) · Onset: ~30 to 45 seconds · Single-dose duration: ~5 to 7 minutes

Anesthetic Practice

Clinical Application

While its everyday use has diminished in the operating room, methohexital remains essential for a very specific set of procedures where its unique excitatory properties are actually seen as a benefit.

Electroconvulsive therapy (ECT): This is the absolute primary modern use case. Because methohexital lowers the threshold for seizures to occur, it allows the psychiatrist to reliably induce a therapeutic seizure. Drugs like propofol actively fight the seizure, making the therapy much less effective.
Cardioversion: It is occasionally used to briefly sedate a patient while their heart is electrically shocked back into a normal rhythm, since the procedure only takes a few minutes.
Pediatric imaging (historical): In the past, it was often administered rectally to sedate small children for magnetic resonance imaging (MRI) scans, though modern practice has largely shifted to safer alternatives.

Body-Wide Effects

Cardiovascular: The drug causes a **dose-dependent drop in blood pressure** along with a compensatory increase in the patient’s heart rate.
Respiratory: This is the most critical risk. Methohexital triggers **profound central respiratory depression**, reliably causing a patient to completely stop breathing (a state known as apnea) upon induction.
CNS: Unlike most anesthetics, it actively **lowers the seizure threshold**. It also frequently triggers myoclonus (involuntary muscle twitching) and intense hiccups as the patient drifts off to sleep.
Contraindications: It is absolutely contraindicated in patients with porphyria, a rare genetic blood disorder, as barbiturates can trigger a sudden and life-threatening crisis.

Medicolegal

Litigation Themes

Because it is so often used in rapid, high-turnover environments outside of the main operating room, malpractice claims surrounding methohexital are highly concentrated in a few specific areas of practice.

Failure to rescue an airway: Apnea is an expected pharmacological consequence of an induction dose. Lawsuits routinely center on scenarios where a provider pushed the drug and then failed to recognize that the patient was not breathing, leading to severe hypoxia (lack of oxygen) and brain injury.
Extravasation injuries: If an intravenous catheter slips out of the vein, the highly alkaline methohexital solution is pumped directly into the patient’s arm tissue. This causes severe chemical burns and tissue necrosis, which can lead to permanent nerve damage and scarring.
Physical injury from excitatory movements: The drug induces intense muscle twitching and erratic movements as consciousness is lost. Claims often arise when a patient falls off the procedure table or strikes a limb against hard equipment because they were not properly secured prior to injection.
Inadequate monitoring outside the OR: Since methohexital is predominantly used in psychiatric suites for electroconvulsive therapy, providers sometimes treat the setting casually. Missing a critical drop in oxygen levels because the continuous monitoring equipment was inadequate or ignored is a highly recurring pattern in litigation.

Best Practice

Methohexital is unapologetically fast and profound in its effects. The central medicolegal takeaway is that you are intentionally taking away a patient’s ability to breathe for 5 minutes in environments that are often outside the traditional operating room. Strict adherence to continuous capnography (monitoring exhaled carbon dioxide) and having immediate backup airway equipment ready is non-negotiable. Anticipating the drug’s chaotic excitatory movements by physically securing the patient before pushing the syringe will prevent the most common mechanical injuries seen in claims.

References

Avramov MN, Husain MM, White PF. The comparative effects of methohexital, propofol, and etomidate for electroconvulsive therapy. Anesth Analg. 1995;81(3):596–602.
FDA. Brevital Sodium (methohexital sodium) prescribing information. Par Pharmaceutical.
Miner JR, Biros MH, Krieg S, et al. Randomized clinical trial of propofol versus methohexital for procedural sedation during fracture and dislocation reduction in the emergency department. Acad Emerg Med. 2003;10(9):931–937.
Stoelting RK. Pharmacology and Physiology in Anesthetic Practice. 4th ed. Lippincott Williams & Wilkins; 2006.